Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
A phase II clinical trial with glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) has shown efficacy in preserving residual insulin secretion in children and adolescents with recent-onset type 1 diabetes (T1D). We have performed a 4-year follow-up study of 59 of the...
Guardado en:
Autores principales: | Stina Axelsson, Mikael Chéramy, Maria Hjorth, Mikael Pihl, Linda Akerman, Emanuela Martinuzzi, Roberto Mallone, Johnny Ludvigsson, Rosaura Casas |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7beb2246337149e8b59df7e8f7bc3c5c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The last will: Estate divisions as a testament of to whom altruism is directed.
por: Mikael Elinder, et al.
Publicado: (2021) -
Alum Pickering Emulsion as Effective Adjuvant to Improve Malaria Vaccine Efficacy
por: Qiuting Chen, et al.
Publicado: (2021) -
Psychometric Properties of The Goldberg Anxiety and Depression Scale (GADS) In Ecuadorian Population
por: Geovanny Genaro Reivan-Ortiz, et al.
Publicado: (2019) -
IN VITRO ANTIFUNGAL ACTIVITY OF POTASH ALUM AGAINST CANDIDA ALBICANS ON ACRYLIC RESIN
por: Muhammad Irshad, et al.
Publicado: (2020) -
Adult and embryonic GAD transcripts are spatiotemporally regulated during postnatal development in the rat brain.
por: Anke Popp, et al.
Publicado: (2009)